Tyra Biosciences, Inc. (TYRA)
NASDAQ: TYRA · Real-Time Price · USD
15.83
+0.47 (3.06%)
Nov 22, 2024, 4:00 PM EST - Market closed
Tyra Biosciences Employees
Tyra Biosciences had 49 employees as of December 31, 2023. The number of employees increased by 11 or 28.95% compared to the previous year.
Employees
49
Change (1Y)
11
Growth (1Y)
28.95%
Revenue / Employee
n/a
Profits / Employee
-$1,708,980
Market Cap
836.96M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 49 | 11 | 28.95% |
| Dec 31, 2022 | 38 | 13 | 52.00% |
| Dec 31, 2021 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Healthcare Services Group | 33,400 |
| Cytek Biosciences | 676 |
| Castle Biosciences | 610 |
| Paragon 28 | 574 |
| Prothena Corporation | 173 |
| Liquidia | 145 |
| Kura Oncology | 142 |
| Capricor Therapeutics | 102 |
TYRA News
- 9 days ago - Tyra Biosciences to Present at Upcoming Investor Conferences - PRNewsWire
- 15 days ago - Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - PRNewsWire
- 25 days ago - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PRNewsWire
- 4 weeks ago - Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
- 4 weeks ago - Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PRNewsWire
- 4 weeks ago - Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - PRNewsWire
- 4 weeks ago - Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point - Seeking Alpha
- 5 weeks ago - BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug - Benzinga